Table 4 Correlation between number of baseline risk factors and completion of ipilimumab induction therapy (3 mg/kg every 3 weeks for a total of four doses)
Number of risk factors | ||||
|---|---|---|---|---|
0 | 1 | 2 | 3 | |
Received BRAF inhibitor first and ipilimumab upon disease progression (n = 28) | ||||
Slow progressors (n = 16) | 11 | 3 | 2 | 0 |
Response to ipilimumab | PR (n = 3); SD (n = 6); PD (n = 2) | PR (n = 3) | PR (n = 1); PD (n = 1) | - |
Rapid progressors (n = 12) | 0 | 1 | 7 | 4 |
Response to ipilimumab | - | SD (n = 1) | NE (n = 4); PD (n = 3) | NE (n = 3); PD (n = 1) |
Received ipilimumab first and a BRAF inhibitor upon disease progression (n = 6) | ||||
Completed induction regimen (n = 6) | 2 | 2 | 2 | 0 |
Response to ipilimumab | PR (n = 1); PD (n = 1) | PD (n = 2) | SD (n = 2) | - |